Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 29, 2016. The document serves as a transaction notification regarding insider trading activities under the UK Market Abuse Regulation, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transaction prices and volumes:
- American Depositary Shares (ADSs): Transaction price of $43.58 per share; volume of 2,300 shares.
- Ordinary Shares: Transaction price of £16.49 per share; volume of 11,060 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses two specific transactions involving Persons Discharging Managerial Responsibilities (PDMR) or persons closely associated with them.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly details the following transactions executed on September 22, 2016:
- Dr. K. Slaoui (PCA of Dr. M. M. Slaoui): Award of 2,300 ADSs under the Company's 2009 Share Value Plan.
- Mrs. V. A. Whyte (Company Secretary): Award of 11,060 Ordinary Shares under the Company's 2009 Share Value Plan.
Investor Verification Checklist
- Verify the total number of shares awarded to insiders under the 2009 Share Value Plan for the quarter.
- Confirm the market price of ADSs and Ordinary Shares on September 22, 2016, to validate the transaction prices listed.
- Review the full 20-F annual report for comprehensive financial metrics not included in this transaction notification.